

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX CORP.  
APOTEX, INC.  
Petitioner

v.

ALLERGAN, INC.  
Patent Owner

U.S. Patent No. 8,633,162

---

*Case To be assigned*

---

**Declaration of Harry C. Boghigian**

**TABLE OF CONTENTS**

|      |  |    |
|------|--|----|
| I.   | Introduction.....  | 2  |
| II.  | Summary of opinions.....   | 3  |
| III. | My Background and Qualifications.....  | 4  |
| IV.  | Documents Reviewed .....   | 10 |
| V.   | My understanding of commercial success.....  | 15 |
| VI.  | Background.....  | 16 |
| VII. | RESTASIS <sup>®</sup> 's performance does not provide evidence of commercial success for the claims of the '162 patent .....     | 20 |
| A.   | RESTASIS <sup>®</sup> 's sales are driven by commercial factors rather than novel features of the '162 patent's claims.....      | 21 |
| B.   | Allergan's market analysis is faulty.....  | 26 |
| 1.   | Allergan's analysis of sales performance improperly focuses on net revenue .....   | 26 |
| 2.   | Allergan's unduly narrow definition of the U.S. market results in a significantly overstated share of the market.....            | 27 |
| 3.   | Allergan overlooks a blocking patent .....   | 31 |
| 4.   | Allergan's analysis fails to establish a nexus between U.S. sales and any alleged novel aspect of the '162 patent's claims ..... | 34 |

I, Harry C. Boghigian, hereby declare as follows.

**I. Introduction**

1. I am over the age of eighteen and competent to make this declaration.
2. I have been retained as an expert witness on behalf of APOTEX CORP. and APOTEX, INC. for the above-captioned *inter partes* review (IPR). I am being compensated for my time in connection with this IPR at my standard consulting rate, which is \$695 per hour. No part of my compensation is affected by the outcome of this matter or the nature of my opinions in this declaration. I understand that the petition for *inter partes* review involves U.S. Patent No. 8,633,162 ("the '162 patent"), Exhibit APO1001, which resulted from U.S. Application No. 13/967,179 ("the '179 application"), filed on August 14, 2013, naming Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, and David F. Power as inventors. The '162 patent issued on January 21, 2014, from the '179 application. The '162 patent claims the benefit of a provisional application that was filed September 15, 2003. I further understand that, according to the USPTO records, the '162 patent is currently assigned to Allergan, Inc.
3. I understand that the '162 patent is directed generally to the field of ophthalmic drug delivery and formulation, and more specifically to methods and compositions for treating an eye of a human or animal having dry eye disease. APO1001, 1, Abstract. I also understand that the compositions recited in the

methods of the '162 patent contain several components, including 0.05% cyclosporin A and 1.25% castor oil. APO1001, 11, 15:22-30.

## **II. Summary of opinions**

4. I have been asked to assess whether there is any commercial success attributable to the '162 patent. My declaration focuses on the alleged commercial success of RESTASIS<sup>®</sup>, which I understand Allergan has asserted is a commercial embodiment of claims of the '162 patent. APO1019, 2175:¶2.

5. Briefly, for at least the reasons set forth below, it is my opinion that the marketplace performance of RESTASIS<sup>®</sup> does not evince commercial success of the '162 patent's claims:

- RESTASIS<sup>®</sup>'s world-wide sales revenue, of which its U.S. sales revenue makes up the majority, does not establish commercial success for the '162 patent's claims because it is driven by extrinsic, commercial factors that are unrelated to the '162 patent, such as Allergan's established position in the market, its effective marketing of RESTASIS<sup>®</sup>, and the growing market for treating dry eye/KCS.
- Allergan's analysis of RESTASIS<sup>®</sup>'s sales performance is misleading. Allergan provides evidence of net revenue rather than unit and prescription sales, and it does not attempt to establish market share for global sales. Its analysis of RESTASIS<sup>®</sup>'s U.S. market share is overstated because Allergan's definition of

the relevant market is unduly narrow. Allergan stated: "As there is no other FDA-approved therapeutic treatment for dry eye available on the US market, Restasis® owns 100% of the market share." And even if Allergan's definition of the market was not flawed, a blocking patent prevented meaningful competition. Further, Allergan's analysis ignores the existence of four unexpired U.S. patents that also encompass RESTASIS®. Allergan also failed to establish a nexus with any alleged novel features of the '162 patent's claims that account for RESTASIS®'s sales.

### **III. My Background and Qualifications**

6. In formulating my opinions, I have relied upon my training, knowledge, and experience in the area of product commercialization and market analysis as it relates to intellectual property matters.

7. I am a pharmaceutical executive with more than 40 years' experience in the commercialization and marketing of prescription pharmaceutical products. In 2001, I founded Pharma Consultants LLC, a New Jersey-based consulting firm serving start-up, small- to medium-size healthcare companies, and advertising agencies, in all areas of pharmaceutical sales and marketing. Companies I have consulted for include entrepreneurs, small-medium size companies and start-ups like EyeGene Bioscience USA, CJ Pharma, CSP Technologies Inc., Dendrite International, and Morphonics LLC. In 2003, I co-founded PBN PHARMA LLC, a

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.